173 related articles for article (PubMed ID: 17868065)
1. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients.
Takemoto SK; Pinsky BW; Schnitzler MA; Lentine KL; Willoughby LM; Burroughs TE; Bunnapradist S
Am J Transplant; 2007 Dec; 7(12):2704-11. PubMed ID: 17868065
[TBL] [Abstract][Full Text] [Related]
2. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression.
Pinsky BW; Takemoto SK; Lentine KL; Burroughs TE; Schnitzler MA; Salvalaggio PR
Am J Transplant; 2009 Nov; 9(11):2597-606. PubMed ID: 19843035
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
[TBL] [Abstract][Full Text] [Related]
4. Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients.
McAdams-DeMarco MA; Law A; Tan J; Delp C; King EA; Orandi B; Salter M; Alachkar N; Desai N; Grams M; Walston J; Segev DL
Transplantation; 2015 Apr; 99(4):805-10. PubMed ID: 25393156
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients.
Sollinger HW; Sundberg AK; Leverson G; Voss BJ; Pirsch JD
Transplantation; 2010 Feb; 89(4):446-51. PubMed ID: 20177347
[TBL] [Abstract][Full Text] [Related]
6. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.
Knoll GA; MacDonald I; Khan A; Van Walraven C
J Am Soc Nephrol; 2003 Sep; 14(9):2381-6. PubMed ID: 12937317
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.
Hardinger KL; Brennan DC; Lowell J; Schnitzler MA
Transpl Int; 2004 Nov; 17(10):609-16. PubMed ID: 15517170
[TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients.
Roberti I; Reisman L
Pediatr Transplant; 1999 Aug; 3(3):231-5. PubMed ID: 10487285
[TBL] [Abstract][Full Text] [Related]
12. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
Sabbatini M; Capone D; Gallo R; Pisani A; Polichetti G; Tarantino G; Gentile A; Rotaia E; Federico S
Fundam Clin Pharmacol; 2009 Oct; 23(5):617-24. PubMed ID: 19656208
[TBL] [Abstract][Full Text] [Related]
13. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low-dose mycophenolate mofetil therapy for Taiwanese renal transplantation patients receiving primary cyclosporine immunosuppression.
Tsai MK; Hu RH; Lee CJ; Lee PH
J Formos Med Assoc; 2002 Sep; 101(9):616-21. PubMed ID: 12645188
[TBL] [Abstract][Full Text] [Related]
15. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients.
Tierce JC; Porterfield-Baxa J; Petrilla AA; Kilburg A; Ferguson RM
Clin Transplant; 2005 Dec; 19(6):779-84. PubMed ID: 16313325
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients.
Schweitzer EJ; Yoon S; Fink J; Wiland A; Anderson L; Kuo PC; Lim JW; Johnson LB; Farney AC; Weir MR; Bartlett ST
Transplantation; 1998 Jan; 65(2):242-8. PubMed ID: 9458022
[TBL] [Abstract][Full Text] [Related]
17. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
18. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C.
Luan FL; Schaubel DE; Zhang H; Jia X; Pelletier SJ; Port FK; Magee JC; Sung RS
Transplantation; 2008 Jun; 85(11):1601-6. PubMed ID: 18551066
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
20. Basiliximab induction in renal transplantation: long-term outcome.
Atlani M; Sharma RK; Gupta A
Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
